Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.

Responsive image

Bevacizumab

Bevacizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetVEGF-A
Clinical data
Pronunciation/ˌbɛvəˈsɪzjʊmæb/[1]
Trade namesAvastin, others
Other namesbevacizumab gamma
Biosimilarsbevacizumab-adcd,[2] bevacizumab-awwb,[3] bevacizumab-bvzr,[4] bevacizumab-maly,[5] bevacizumab-tnjn, Abevmy,[6] Alymsys,[7][5] Avzivi,[8][9] Aybintio,[10] Bambevi,[11] Bevacip,[12] Bevaciptin,[12] Equidacent,[13] Mvasi,[14] Onbevzi,[15][16] Oyavas,[17] Vegzelma,[2][18][19] Zirabev[20]
AHFS/Drugs.comMonograph
MedlinePlusa607001
License data
Pregnancy
category
Routes of
administration		Intravenous, intravitreal
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (IV only)
Elimination half-life20 days (range: 11–50 days)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6638H10160N1720O2108S44
Molar mass149198.87 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease.[30][28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma.[31] In many of these diseases it is used as a first-line therapy.[30][28] For age-related macular degeneration it is given by injection into the eye (intravitreal).[30]

Common side effects when used for cancer include nose bleeds, headache, high blood pressure, and rash.[30] Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection.[30] When used for eye disease side effects can include vision loss and retinal detachment.[30] Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor.[30] It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A), in other words anti–VEGF therapy.[30]

Bevacizumab was approved for medical use in the United States in 2004.[32][30] It is on the World Health Organization's List of Essential Medicines.[33]

  1. ^ "Bevacizumab Injection: MedlinePlus Drug Information". NLM.nih.gov. 28 February 2014. Archived from the original on 25 March 2014.
  2. ^ a b c Cite error: The named reference Vegzelma FDA label was invoked but never defined (see the help page).
  3. ^ a b "Mvasi- bevacizumab-awwb injection, solution". DailyMed. 25 June 2019. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  4. ^ a b "Zirabev- bevacizumab-bvzr injection, solution". DailyMed. 27 January 2020. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  5. ^ a b c "Alymsys- bevacizumab-maly injection, solution". DailyMed. 13 April 2022. Archived from the original on 10 June 2022. Retrieved 20 April 2022.
  6. ^ a b Cite error: The named reference Abevmy EPAR was invoked but never defined (see the help page).
  7. ^ a b Cite error: The named reference Alymsys EPAR was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference Avzivi EPAR was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference Avzivi PI was invoked but never defined (see the help page).
  10. ^ a b Cite error: The named reference Aybintio EPAR was invoked but never defined (see the help page).
  11. ^ Cite error: The named reference Bambevi SBD was invoked but never defined (see the help page).
  12. ^ a b Cite error: The named reference AU biosimilar was invoked but never defined (see the help page).
  13. ^ a b Cite error: The named reference Equidacent EPAR was invoked but never defined (see the help page).
  14. ^ a b Cite error: The named reference Mvasi EPAR was invoked but never defined (see the help page).
  15. ^ a b Cite error: The named reference Onbevzi EPAR was invoked but never defined (see the help page).
  16. ^ a b "Onbevzi APMDS". Therapeutic Goods Administration (TGA). 6 February 2024. Archived from the original on 8 February 2024. Retrieved 7 March 2024.
  17. ^ a b Cite error: The named reference Oyavas EPAR was invoked but never defined (see the help page).
  18. ^ a b Cite error: The named reference Vegzelma EPAR was invoked but never defined (see the help page).
  19. ^ a b c "Vegzelma APMDS". Therapeutic Goods Administration (TGA). 18 September 2023. Archived from the original on 2 January 2024. Retrieved 7 March 2024.
  20. ^ a b Cite error: The named reference Zirabev EPAR was invoked but never defined (see the help page).
  21. ^ a b "Abevmy". Therapeutic Goods Administration (TGA). 15 September 2021. Archived from the original on 16 September 2021. Retrieved 17 September 2021.
  22. ^ "Bevacizumab Use During Pregnancy". Drugs.com. 30 July 2019. Archived from the original on 18 March 2020. Retrieved 18 March 2020.
  23. ^ "AusPAR: Bevacizumab". Therapeutic Goods Administration (TGA). 2 February 2022. Archived from the original on 31 May 2022. Retrieved 12 June 2022.
  24. ^ "Australian Public Assessment Report for Vegzelma" (PDF). Department of Health and Aged Care. 22 February 2024. Retrieved 18 August 2024.
  25. ^ "Summary Basis of Decision for Vegzelma". Health Canada. 2 May 2023. Archived from the original on 10 March 2024. Retrieved 18 June 2023.
  26. ^ "Vegzelma Product information". Health Canada. 3 January 2023. Archived from the original on 10 March 2024. Retrieved 18 June 2023.
  27. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
  28. ^ a b c "Avastin- bevacizumab injection, solution". DailyMed. 28 June 2019. Archived from the original on 27 July 2020. Retrieved 18 March 2020.
  29. ^ Cite error: The named reference Avastin EPAR was invoked but never defined (see the help page).
  30. ^ a b c d e f g h i "Bevacizumab". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
  31. ^ "Bevacizumab". National Cancer Institute. 5 October 2006. Archived from the original on 10 April 2020. Retrieved 22 December 2023.
  32. ^ "Drug Approval Package: Avastin (Bevacizum) NDA #125085". U.S. Food and Drug Administration (FDA). 8 March 2005. Archived from the original on 8 April 2021. Retrieved 29 December 2021.
  33. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

Previous Page Next Page






بيفاسيزوماب Arabic بواسیزامب AZB Bevacizumab Catalan Bevacizumab German Bevacizumab Spanish Bevatsisumaab ET بواسیزامب FA Bevasitsumabi Finnish Bévacizumab French אווסטין HE

Responsive image

Responsive image